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Background: Gliosarcoma (GS) is a rare histopathologic variant of glioblastoma (GBM)
characterized by a biphasic growth pattern consisting of both glial and sarcomatous
components. Reports regarding its relative prognosis compared to conventional GBM
are conflicting and although GS is treated as conventional GBM, supporting evidence is
lacking. The aim of this study was to characterize demographic trends, clinical outcomes
and prognostic variables of GS patients receiving standardized therapy and compare
these to conventional GBM.
Methods: Six hundred and eighty GBM patients, treated with maximal safe resection
followed by radiotherapy with concomitant and adjuvant temozolomide at a single
institution, were retrospectively reevaluated by reviewing histopathological records
and tumor tissue for identification of GS patients. Clinico-pathological- and tumor
growth characteristics were obtained via assessment of medical records and imaging
analysis. Kaplan-Meier survival estimates were compared with log-rank testing, while
Cox-regression modeling was tested for prognostic factors in GS patients.
Results: The cohort included 26 primary gliosarcoma (PGS) patients (3.8%) and
7 secondary gliosarcoma (SGS) patients (1.0%). Compared to conventional GBM
tumors, PGS tumors were significantly more often MGMT-unmethylated (73.9%) and
located in the temporal lobe (57.7%). GS tumors often presented dural contact, while
extracranial metastasis was only found in 1 patient. No significant differences were found
between PGS and conventional GBM in progression-free-survival (6.8 and 7.6 months,
respectively, p = 0.105) and in overall survival (13.4 and 15.7 months, respectively, p =
0.201). Survival following recurrence was not significantly different between PGS, SGS,
and GBM. Temporal tumor location and MGMT status were found associated with PGS
survival (p = 0.036 and p = 0.022, respectively).
Conclusion: Despite histopathological and location difference between GS and GBM
tumors, the patients present similar survival outcome from standardized treatment. These
findings support continued practice of radiation and temozolomide for GS patients.
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INTRODUCTION
Glioblastoma (GBM, WHO grade IV glioma) is the most
common and aggressive primary brain tumor in adults with
a median overall survival (OS) of around 15 months (1).
Gliosarcoma (GS) is a rare histopathological variant of isocitrate
dehydrogenase (IDH)-wildtype GBM and accounts for ∼2% of
all GBM (1–5), although frequencies up to 8% have been reported
(6, 7). Histologically, GS tumors are characterized by a biphasic
growth pattern consisting of both glial components and areas
of sarcomatous, mesenchymal differentiation often resembling
fibrosarcoma (7). The mesenchymal components may also
comprise chondral (8, 9), osteoid (9–11), osteochondral (12,
13), myomatous (14, 15), and/or lipomatous (16) elements. The
pathogenesis of GS remains unknown, but findings of common
genetic alterations in both the gliomatous and sarcomatous
components support the hypothesis that GS tumors are of
monoclonal origin (17–20).
GS are termed primary gliosarcoma (PGS) if they arise de
novo without any prior GBM diagnosis, whereas GS occurring
after treatment of conventional GBM are termed secondary
gliosarcoma (SGS). SGS are distinguished from radiation therapy
(RT)-induced GS, which arise after intracranial RT in patients
without any prior presence of GBM (21–24). GS most often
affects adults in the fifth to seventh decade of life, with a male
predominance, and has a temporal lobe predilection (4–6, 25–
27). On imaging GS lesions typically present as a well-demarcated
supratentorial mass often peripherally located and abutting dura
(26–31). While these imaging features are more likely to occur
in GS compared to conventional GBM, it is still not possible to
diagnose GS by imaging alone (27, 30). The growth pattern of GS
tumorsmay differ from that of conventional GBM, as extracranial
(EC) metastasis has been reported in up to 11% of GS (32), which
is far more than among conventional GBM patients, with <2%
of cases metastasizing (33, 34). Additionally, cases of skull base
invasion and EC extension have been described (30, 35, 36).
While an exceptional poor prognosis for GS has been
reported (5, 29), several studies showed no significant differences
in outcome between GS and conventional GBM (3, 25, 37).
GS patients are typically managed as conventional GBM in
accordance with the Stupp’s regimen of trimodality therapy
including maximal safe resection, RT with concurrent and
adjuvant temozolomide (TMZ) based chemotherapy (38).
However, solid supporting evidence for this strategy is lacking.
Only few studies have conducted regular comparisons of
standardized concomitant RT and chemotherapy in GS
vs. conventional GBM patients and these are disposed to
uncertainties like insufficient patient number or lack of
information on precise therapeutic intervention (25, 29, 37, 39).
For GBM identified prognostic factors include patient age,
performance status (PS), extent of resection (EoR), corticosteroid
use at start of treatment and methylation of the gene promoter of
O6-methylguanine-DNA-methyltransferase (MGMT) (40, 41),
a DNA repair protein inhibiting the effect of TMZ (42). Patient
age and EoR were also found prognostic among GS patients
in a large registry study (37) but prognostic influence in GS of
other variables such as MGMT promoter methylation remains
uncertain (30, 37, 43).
In this report, we retrospectively reviewed a series of
GS patients to characterize demographic trends, prognostic
variables and clinical outcomes. To evaluate the current
clinical management of GS we compared survival after
standardized treatment for PGS patients relative to conventional
GBM patients.
METHODS
Patients
Six hundred and eighty patients were from January 2005 to
December 2016 diagnosed with GBM and treated according
to Stupp’s regimen at Rigshospitalet, Copenhagen, Denmark.
All patients were retrospectively evaluated for study eligibility
by reviewing the histopathological reports from diagnosis of
tumor tissue from both primary and later GBM surgeries.
Two patients without available histopathological reports were
excluded and reports from the remaining 678 patients were
reviewed for description of a sarcomatous appearance and/or
component of the tumor. Forty-three patients were selected for
histological reevaluation based on the reports, of which two
had to be excluded due to lacking histopathological specimens.
The histopathological specimens of the remaining 41 patients’
tumor tissue were evaluated for presence of a sarcomatous
component. The GS diagnosis was made based on a biphasic
growth pattern on hematoxylin- and eosin (HE)-staining as well
as glial fibrillary acidic protein (GFAP)-staining demonstrating
GFAP-positive gliomatous components and GFAP-negative
sarcomatous components containing neoplastic spindle-shaped
cells. Furthermore, the diagnosis was supported via evaluation
for collagen richness in the sarcomatous components by Van
Gieson staining. Evaluation was performed independently by
two assessors (one being a trained neuropathologist) and
consensus was followingly achieved. Both assessors were blinded
to clinical data. The GS tumors presented a highly heterogeneous
histological pattern of sarcomatous components. Of this reason
there was no cut-off to the extent of sarcomatous components of
the tumor, all tumors containing a sarcomatous component were
considered as GS. Primary gliosarcomas (PGS) were defined as de
novo tumors in patients with no prior history of GBM. Secondary
gliosarcomas (SGS) were defined based on histopathological
diagnosis of GS at reresection following previous diagnosis and
treatment of conventional GBM. Patient selection for this study
is demonstrated in the REMARK diagram in Figure 1.
Treatment
All patients, irrespectively of age, received first-line Stupp’s
regimen (i.e., TMZ 75 mg/m2/day plus RT at a dose of 60Gy to
the planning target volume in 30 fractions with 5 fractions/week,
followed by up to 6 courses of adjuvant TMZ therapy each
consisting of 150–200 mg/m2/day TMZ for 5 days followed by
23 days without therapy). More details on administration has
previously been described (40). After progression on primary
therapy, 250 patients underwent reresection and 280 received
bevacizumab in most cases given together with irinotecan or
lomustine (CCNU) dependent on the local guidelines at the
time (44). Selected patients further received different types
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FIGURE 1 | REMARK diagram for identification of GS and GBM patients.
of experimental treatment either before or after bevacizumab
recurrence therapy.
Assessment of Patient and Tumor Growth
Characteristics
Baseline demographic information and treatment-related
variables including age, sex, PS (ECOG score), anatomic
tumor localization, multifocality, tumor size, EoR, use of
corticosteroids, site of recurrence and re-resection were collected
via medical records when available. For the PGS patients,
when available, preoperative, 72 h post-operative and later
magnetic resonance imaging (MRI) were re-assessed by a
trained neuroradiologist regarding anatomical localization,
multifocality, contact to dura, EoR and metastatic spread. EoR
was defined as subtotal if residual tumor tissue was ≥ 1 × 1 ×
1 cm and site of recurrence was defined as distant if more than
1 cm from primary tumor location. If not available on imaging,
the medical records, including histopathological reports, were
searched for information on distant intracranial recurrence,
EC extension and distant metastases. Status for mutation of
IDH1 and promoter methylation of MGMT were obtained
during routine tissue examination from primary GBM/GS
surgery by varying detection methods dependent on the time of
analysis. IDH1 was either examined by immunohistochemistry
(IHC) using anti-IDH1 R132H antibody (clone H09, Dianova,
1:700 dilution) or by Multiplex Ligation-dependent Probe
Amplification (MLPA), using the SALSA MLPA kit P088 (MRC
Holland, Amsterdam, the Netherlands). MGMT promoter
methylation was from 2014 analyzed by pyrosequencing using
the Therascreen MGMT Pyro kit (Qiagen) considering a
mean methylation above 10% as positive. Until then it was
determined indirectly by a non-standardized IHC method
using anti-MGMT antibody (MAB16200, Millipore, 1:200).
In previous publication we found this indirect method for
estimation of MGMT promoter methylation to be strongly
associated with results obtained by pyrosequencing, although it
is less sensitive and underestimate the number of unmethylated
samples (45).
Survival Endpoints and Statistical
Evaluation
Patient survival was calculated as follows: Progression-free-
survival (PFS) was defined as the time from initial GBM/GS
diagnosis until first recurrence with radiological or clinical
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progression or alternative death without prior disease recurrence.
OS was calculated as the time from diagnosis until date of
death and survival from recurrence as the time from first
recurrence until death. OS for SGS patients was calculated
from the date of histopathologic confirmed GS diagnose until
time of death. Time to SGS was calculated from date of
initial GBM diagnosis until date of recurrence resection with
histopathologically confirmation of GS.
Survival probabilities were estimated using Kaplan-Meier
method and survival differences between the histopathological
groups evaluated with Mantel-Cox log rank test. Comparison
of clinical characteristics for PGS and GBM cohorts were done
using Fisher’s exact test and Mann–Whitney U-Test. Univariate
analyses were conducted by Cox proportional hazards modeling
also estimating hazard ratios (HR) with a 95% confidence interval
(CI). P ≤ 0.05 were considered significant. Calculations were
performed using SPSS (v22.0, IBM Corp., Armonk, NY).
RESULTS
Characteristics of PGS Patients Compared
to Conventional GBM
Among 680 GBM patients diagnosed from 2005 to 2016
and treated according to Stupp’s regimen we identified 643
conventional GBM patients, 26 PGS patients (3.8% of all GBM)
and 7 SGS patients (1.0% of all GBM), excluded patients
= 4 (REMARK diagram, Figure 1). Comparison of clinico-
pathological characteristics of PGS and conventional GBM
(Table 1) revealed no significant differences in regard to median
patient age at diagnosis (59.7 vs. 60.3, p = 0.804), sex (73.1
vs. 65% males, p = 0.529), pretreatment PS (61.5 vs. 61.9%
with PS = 0, p = 1.000) or corticosteroid use at treatment
start (76.9 vs. 61.1%, p = 0.148). Additionally, no differences
were found regarding multifocal disease (multifocal in 19.2 vs.
12%, p = 0.353), median tumor size (1,610 vs. 1,600 mm2, p =
0.348) or hemisphere laterality (right side in 65.4 vs. 47.1%, p
= 0.119). PGS tumors were most often located in the temporal
lobe (57.7%) followed by multilobar location (19.2%), frontal
lobe (15.4%), occipital lobe (3.85%), and parietal lobe (3.85%).
Compared to conventional GBM, PGS tumors were significantly
more frequent located to the temporal lobe (27.5 vs. 57.7%, p
= 0.002). At disease recurrence, registered in all but one of the
PGS patients, no difference was seen regarding having a distant
or local recurrence site in PGS compared to conventional GBM
(p= 0.608) (Supplementary Table 1).
In contrast to conventional GBM, all PGS were IDH1 wildtype
(100%), but statistical analysis did not reveal any significant
difference (p = 0.614). Contrary, there was a significantly
lower frequency of MGMT promoter methylation in PGS when
compared to conventional GBM (26.1 vs. 54.6%, p = 0.009)
(Table 1 and Supplementary Table 2).
EoR at primary surgery was recorded in all 26 PGS patients
who underwent either gross total resection (34.6%) or subtotal
resection (65.4%), a distribution that turned out significantly
different from conventional GBM (p = 0.004) (Table 1).
Otherwise treatment of PGS did not differ significantly from
TABLE 1 | Patient characteristics of conventional GBM and PGS.
Variable GBM
(n = 643)
PGS
(n = 26)
P-value
(PGS vs. GBM)
Age at diagnosis (years),
median (range)
60.3 (17.1–79.6) 59.7 (25.6-76.8) 0.804
Sex, n (%) 0.529
Male 418 (65.0) 19 (73.1)
Female 225 (35.0) 7 (26.9)
PS, n (%) 1.000
0 393 (61.9) 16 (61.5)
1–2 242 (38.1) 10 (38.5)
Missing 8 0
Corticosteroid use*, n (%) 0.148
No 248 (38.9) 6 (23.1)
Yes 389 (61.1) 20 (76.9)
Missing 6 0
Location, lobe**, n (%)
Frontal 132 (20.6) 4 (15.4) 0.627
Temporal 176 (27.5) 15 (57.7) 0.002
Parietal 74 (11.5) 1 (3.85) 0.345
Occipital 46 (7.2) 1 (3.85) 1.000
Multilobar 163 (25.4) 5 (19.2) 0.646
Profound 17 (2.7) 0 (0.0)
Other 33 (5.1) 0 (0.0)
Missing 2 0
Location, hemisphere, n (%) 0.119
Right 301 (47.1) 17 (65.4)
Left 293 (45.9) 7 (26.9)
Profound/bilateral 45 (7.0) 2 (7.7)
Missing 4 0
Multifocal disease, n (%) 0.353
No 564 (88) 21 (80.8)
Yes 77 (12) 5 (19.2)
Missing 2 0
Tumor size (mm2 ), median
(range)
1600.0
(25–6,150)
1610.0
(625–5,046)
0.348
Missing 328 9
EoR, primary surgery, n (%) 0.004
Biopsy 100 (15.7) 0 (0.0)
Subtotal resection 237 (37.2) 17 (65.4)
Gross total resection 300 (47.1) 9 (34.6)
Missing 6 0
Adjuvant TMZ therapy, n (%) 0.293
≥6 cycles 227 (35.4) 6 (23.1)
<6 cycles 415 (64.6) 20 (76.9)
Missing 1 0
MGMT status***, n (%) 0.009
Methylated 292 (54.6) 6 (26.1)
Unmethylated 243 (45.4) 17 (73.9)
Missing 108 3
IDH1 status, n (%) 0.614
Wild-type 372 (95.6) 22 (100.0)
Mutated 17 (4.4) 0 (0.0)
Missing 254 4
Statistical tests: Mann-Whitney U-test (Age, tumor size); Fisher’s exact test (Sex,
PS, Corticosteroid use, Location, Multifocal disease, EoR, adjuvant therapy, MGMT
status, IDH1 status). GBM, glioblastoma; PGS, primary gliosarcoma; PS, performance
status; EoR, extent of resection; TMZ, temozolomide; MGMT, O6-methylguanine-DNA-
methyltransferase; IDH1, isocitrate dehydrogenase 1. *Prednisolone ≥ 10mg. **Tumor
involving more than one lobe. ***Estimated directly by pyrosequencing or indirectly by
IHC, details is shown in Supplementary Table 2.
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TABLE 2 | Imaging characteristics of PGS tumors.
Case Sex Age range, debut Location Multifocal, debut EoR, primary surgery Dural contact Distant intracranial recurrence EC extension Distant metastasis
1 M 50–59 L Temporal ÷ STR* Unk ÷a ÷a ÷a
2 F 50–59 L Temporal ÷ STR* + ÷ ÷ ÷
3 F 60–69 R Frontoparietal ÷ GTR* Unk ÷a ÷a ÷a
4 M 40–49 L Frontotemporal ÷ STR* + ÷ ÷ ÷
5 M 70–79 R Temporal ÷ STR* ÷b ÷ ÷ ÷
6 M 60–69 R Frontoparietal ÷ GTR ÷ ÷ ÷ ÷
7 M 60–69 Bilat Frontal + STR + ÷ ÷ ÷
8 M 60–69 R Temporooccipital + STR + ÷ ÷ ÷
9 M 50–59 L Temporal ÷ STR + (progression) ÷ ÷ ÷
10 F 50–59 L Frontal ÷ STR + ÷ ÷ ÷
11 M 50–59 R Temporal ÷ GTR + ÷ + (subcutis) ÷
12 M 40–49 R Temporal ÷ STR* + ÷ ÷ ÷
13 F 40–49 R Temporal ÷ STR + ÷ + (subcutis) ÷
14 M 60–69 R Temporal + STR + ÷ ÷ ÷
15 M 50–59 R Temporal ÷ GTR + + (R frontal, cerebellar) ÷ ÷
16 F 70–79 R Occipital ÷ STR + ÷ ÷ ÷
17 M 70–79 R Temporal ÷ GTR + + (L frontal) ÷ ÷
18 M 60–69 L Temporal ÷ STR + + (L frontotemporal) ÷ ÷
19 M 50–59 R Temporal and occipital + STR* + ÷ ÷ ÷
20 M 40–49 R Temporal + STR* + + (L frontal, temporal, occipital) ÷ ÷
21 M 50–59 R Temporal ÷ STR* + (progression) ÷ ÷ ÷
22 M 20–29 Bilat Frontal ÷ STR ÷ + (fossa posterior, 4. ventricle) ÷ ÷
23 M 70–79 R Frontal ÷ GTR ÷ ÷ ÷ ÷
24 M 60–69 L Parietal ÷ GTR* ÷ ÷ ÷ + (neck)
25 F 60–69 R Temporoparietal ÷ GTR ÷ + (L cerebellar) ÷ ÷
26 F 70–79 R Temporal ÷ GTR* ÷ ÷ ÷ ÷
M, male; F, female; L, left; R, right; EoR, extent of resection; STR, subtotal resection; GTR, gross total resection; Unk, unknown; EC extracranial. *EoR based on surgical records. a Information based on medical records. b Information
based on imaging descriptions.
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conventional GBM, with 6 PGS patients receiving a minimum
of 6 cycles adjuvant TMZ during first-line treatment (p =
0.293), 12 PGS patients undergoing reresection (p = 0.408)
and 10 PGS patients receiving systemic bevacizumab salvage
therapy (p = 0.840), given as bevacizumab and irinotecan
combined (n = 6), or bevacizumab and CCNU combined (n =
4) (Supplementary Table 1). Other systemic salvage therapies for
the PGS patients included CCNUmonotherapy (n= 4), selinexor
(n= 2), palliative TMZ (n= 1), and nintedanib (n= 1). One PGS
patient developed several subcutaneousmetastasis (noduli) in the
neck after 5 series of adjuvant TMZ and had a subtotal removal
of the tumors due to muscle infiltration.
Imaging Characteristics of PGS Patients
Preoperative MRI were available in 23 PGS patients, while 15
PGS patients had available 72 h post-operative MRI (Table 2).
The tumors of 15 patients (58%) presented with dural contact
at time of diagnosis while two additional patients had a tumor
with dural contact at time of progression (case 9 and 21). A total
of 6 PGS patients had distant intracranial recurrence with the
tumor(s) located elsewhere than the primary tumor. Two patients
(case 11 and 13) had at recurrence a tumor growing through
the previous operation channel into the subcutaneous layer of
the scalp. Only one patient (case 24) had EC metastasis in the
neck. The radiological evaluation did not support an association
between tumor location and EoR, multifocality, dural contact,
intracranial spread, or EC growth, respectively.
Characteristics of SGS Patients
Characteristics of the seven SGS patients are displayed in Table 3.
The median age for SGS patients at diagnosis for conventional
GBM was 55 years (range 23–65 years) and SGS developed
in patients of both sexes and with varying PS. These tumors
were both MGMT methylated and unmethylated tumors and
presenting various tumor location, although involvement of the
frontal and parietal lobes was dominating. All SGS patients were
diagnosed at first reresection for conventional GBM, while their
diagnostic tumor tissue from their first surgery did not show
any sarcomatous components, but conventional GBM histology.
One patient did not receive any salvage therapy for SGS and
three patients underwent reresection for recurrent SGS. Salvage
chemotherapy included bevacizumab and irinotecan (n = 3),
bevacizumab and CCNU (n = 1) or cilengetide (n = 1). Two
SGS patients (case 2 and 3) had at time of progression a tumor
growing through the operation channel involving the scalp
and subcutaneous layer, one of these patients (case 3) received
salvage RT.
Patient Outcomes and Prognostic
Variables
All PGS and SGS patients had died before the time of analyses,
while 32 conventional GBM patients were still alive with a follow-
up time of 29–167 months. Figure 2 and Supplementary Table 3
show survival data for the patient groups. PGS patients had a
median PFS of 6.8 months (range 2.3–29.2) and conventional
GBM patients 7.6 months (range 1.1–167.7). Median OS for PGS
patients was 13.4 months (range 2.3–47.4) while conventional
GBM had a median OS of 15.7 months (range 1.1–167.7). We
found no significant difference in median PFS (p = 0.105) or
median OS (p= 0.201) between the groups.
The median time from diagnosis of conventional GBM to
diagnosis of SGS was 10.9 months (range 5.4–19.6 months).
Median survival following SGS diagnosis was 6.6 months (range
1.2–9.0 months), while median OS for SGS patients, from
diagnosis of conventional GBM to date of death, was 18.6 months
(range 12.0–22.3 months) (Table 3). When comparing all three
groups, i.e., conventional GBM, PGS and SGS, there was no
significant difference in median survival from first recurrence
(median 7.4, 5.8, and 8.6 months, respectively, p = 0.694)
(Supplementary Table 3).
To investigate the influence of clinico-pathological variables
on PFS andOS in PGS patients, we performed univariate analysis.
Factors tested were those found significantly different between
PGS and conventional GBM patients (temporal tumor location,
MGMT promoter methylation and EoR at primary surgery)
together with other variables previously demonstrated prognostic
for GBM (age, PS, corticosteroid use) (Supplementary Table 4).
Factors significantly associated with OS included temporal tumor
location (temporal vs. other, HR: 0.41, p = 0.036) and MGMT
promoter methylation (methylated vs. unmethylated, HR: 0.17, p
= 0.022). For PFS MGMT promoter methylation was the solitary
factor showing a significant association (HR: 0.26, p= 0.035).
DISCUSSION
Although GS has been known for over a century (46) and today
is recognized as a distinct histopathologic entity, the best practice
for GS is associated with high uncertainty. The influence of
the sarcomatous abundance in GS tumors has previously been
discussed (47, 48) but recent studies show no association between
the extent of sarcomatous components and median OS of GS
patients (30, 48). Currently there are no guidelines regarding a
cutoff for the extent of sarcomatous component when diagnosing
GS tumors (1) and consequently, all patients with a sarcomatous
component of the tumor in this study were considered GS,
regardless of the sarcomatous quantity. Supporting selection of
this cutoff is our finding of an incidence of PGS patients of
3.8% of all GBM, consistent with earlier estimates of 1.8–8%
(2, 5, 7). Our PGS cohort was also demographically and clinically
comparable with previous described cases of GS (37, 39, 49),
patients were predominantly middle-aged men (M:F ratio 19:7,
median age 59.7) with a tumor located in the temporal lobe
(57.7%). Also, in concordance with GS being a variant of GBM,
IDH-wildtype, and prior reported genetic alterations (50, 51) all
PGS tumors were IDH1-wildtype.
It was recently proposed that the GS diagnosis could be
estimated by preoperatively imaging analysis (27), but this is
conflicted by a study finding a slightly larger area of edema to be
the only distinct feature of GS compared to conventional GBM
tumors upon evaluation of the radiological VASARI feature set
(51). Radiological analysis of our PGS patients revealed that 58%
had a peripheral tumor abutting dura, consistent with previous
reported imaging characteristics (28–31). Skull base invasion and
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TABLE 3 | Characteristics of SGS patients.
Case Sex Age range,
debut
MGMT
status
IDH
status
PS at
debut
Location of
primary GBM
tumor
EOR, GBM GBM treatment
prior to SGS
surgery
Time to SGS
(months)
Location of
SGS
EOR, SGS SGS treatment OS from SGS OS from initial
GBM diagnosis
(months)
1 M 50–59 ÷ WT 1 Frontal STR RT + TMZ (6
cycles adj.)
13.2 Frontal GTR Re-OP for SGS
relapse
9.0 22.3
2 F 60–69 ÷ WT 0 Parieto-
occipital
GTR RT + TMZ (6
cycles adj.)
10.2 Parietal STR 2 cycles
Bev/CCNU,
Re-OP for SGS
relapse
8.0 18.3
3 M 60–69 ÷ WT 1 Frontal STR RT + TMZ (2
cycles adj.)
5.4 Frontal STR 4 cycles Bev/Iri,
salvage RT of
subcutaneous
tumor
6.6 12.0
4 M 50–59 + WT 0 Multifocal
parietal
Biopsy RT + TMZ (0
cycles adj.),
followed by OP
19.3 Fronto-
parietal
STR None 1.2 20.5
5 M 50–59 ÷ Unk 2 Fronto-parietal STR RT + TMZ (2
cycles adj.)
5.7 Fronto-
parietal
STR 4 cycles Bev/Iri 6.7 12.2
6 F 60–69 + WT 0 Temporal STR RT + TMZ (6
cycles adj.)
10.9 Temporal STR 2 cycles Bev/Iri,
Re-OP for SGS
relapse
7.7 18.6
7 F 20–29 Unk Unk 0 Fronto-parietal GTR RT + TMZ (2
cycles adj.),
followed by 2
cycles
Ce/Bev/Iri, 10
cycles Bev/Iri,
2 cycles Bev/Tor
19.6 Parietal STR Experimental
treatment with
Cilengetide
(3 treatments)
2.2 21.8
SGS, secondary gliosarcoma; M, male; F, female; GBM, glioblastoma; MGMT, O6-methylguanine-DNA-methyltransferase; WT, wildtype; PS, performance status; EoR, extent of resection; STR, subtotal resection; GTR, gross total
resection; RT, radiation; TMZ, temozolomide; OP, operation; Ce, cetuximab; Bev, bevacizumab; Iri, irinotecan; Tor, torisel.
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FIGURE 2 | Kaplan–Meier curves for OS, PFS and survival from recurrence. There was no significant difference in PFS (A) or OS (B) between PGS and conventional
GBM. When comparing all GBM, PGS and SGS groups there was no significant difference in survival from recurrence (C).
EC extension has been reported a rarity in GS patients (30, 36)
and we too found only two PGS patients with EC extension. In
contrast to reports of an EC metastasis rate in GS as high as
11% (32), only one PGS patient in our cohort (3.8%) presented
with EC metastases and none of the SGS patients developed
metastasis. Nevertheless, this low incidence of metastatic spread
from GS in our cohort is also supported by other studies, with
Cachia et al. (49) reporting that one PGS patient (4.2%) and
one SGS patient (10%) developed extra-axial metastasis and two
other studies (30, 39) with no incidence of distant metastasis in
cohorts of 15 and 22 PGS patients, respectively. Of notice, while
we found having a temporal tumor location being associated with
improved OS among PGS patients, the radiological exploration
did not reveal this to be specially associated with specific growth
patterns or EoR.
While MGMT promoter methylation is a known prognostic
factor for outcome among GBM patients specifically associated
with TMZ efficacy (41), its influence remains uncertain in PGS
patients with varying reports on frequency of MGMT promoter
methylation and its association with OS. In a study of 12
GS patients with 6 having MGMT promoter methylation and
9 receiving TMZ, Kang et al. (43) found MGMT promoter
methylation to be a positive prognostic factor for OS and PFS.
Also, in a large registry-based study by Frandsen et al. (37)
patients with MGMT promoter methylation trended toward
a better median survival when compared to GS patients
with unmethylated MGMT promoter. However, the number
of patients receiving TMZ was unknown as the specific type
of chemotherapy administrated to patients was not registered
(37). In contrast, Singh et al. (48) detected MGMT promoter
methylation in 5 of 16GS patients treated with TMZ but found no
association to median survival. In this study we found that PGS
patients had a significantly lower frequency of MGMT promotor
methylation (26.1%) when compared to conventional GBM
(54.6%). Still MGMT status was significantly associated with both
PFS and OS for TMZ treated PGS patients in univariate analysis.
That our level for conventional GBM patients having MGMT
promoter methylation was slightly higher than previously
reported (41, 52) must be accredited to the combined use of
pyrosequencing and an indirect IHC detection method, of which
the latter has been found to slightly overestimate number of
methylated tumors compared to standard pyrosequencing (45).
The therapeutic effect of TMZ among GS patients has
been widely discussed and results from trimodality treatment
with TMZ-based chemotherapy are conflicting (53–57). Two
previous studies found no significant improvement in OS among
GS patients receiving RT with concurrent and adjuvant TMZ
compared to RT alone or combined with other chemotherapy
(54, 57). In contrast, one study reported that concurrent and
adjuvant TMZ improved OS at 24 months from 10.2 to 20%
(53) and Adeberg et al. (55) found concomitant TMZ to be
significantly associated with increased OS (p = 0.01) when
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compared to RT alone (55). Even with trimodality treatment GS
has an overall poor prognosis with reported median OS ranging
from 8.3 to 16.7 months (5, 25, 29, 37, 43, 53). Compatible
with this, median OS for PGS patients in our study was 13.5
months. Although differences in survival between GS and GBM
has been reported (5, 39), several studies have failed to reveal any
significant difference in OS between GS and conventional GBM
(2–4, 25, 29, 37). However, only few studies have investigated
difference in survival outcome between GS and conventional
GBM patients both receiving trimodality therapy with TMZ-
based chemotherapy and these have presented varying results.
Damodaran et al. (29) found no significant differences in median
OS between a cohort of 12 GS patients and GBM patients
receiving treatment according with Stupp’s regimen. In a more
recent study, Smith et al. (39) compared 14 PGS patients and
256 conventional GBM patients, all treated with TMZ-based
chemoradiation, and found a significant worse median OS for
PGS patients. In the present study, of nearly twice as many
PGS patients, we found no significant difference in median OS
when compared to conventional GBM patients (13.4 and 15.7
months, respectively, p = 0.201), suggesting that trimodality
treatment is just as effective in both groups and consequently
supporting continuation of the same clinical management of PGS
as conventional GBM.
Our GBM cohort contained 7 SGS patients, all diagnosed
at first recurrence of GBM. The current literature on SGS is
limited and the pathogenesis of SGS remains unknown (23,
24, 49). Our SGS patients did not present any specific features
different from the PGS or GBM patients. Neither did they
receive more aggressive treatment than the remaining cohort,
which has been proposed as a possible cause for development
of these tumors (23). In the largest collective experience with
30 SGS patients, Han et al. (23) reported a median time of 8.5
months from GBM diagnosis to SGS diagnosis and a median
OS of 4.4 months from diagnosis of SGS, with a worse outcome
among patients who received concurrent and adjuvant TMZ for
initial GBM diagnosis. Even though all patients in this study
received aggressive RT/TMZ for initial GBM diagnosis, we found
compared to this previous study both a longer median time to
SGS diagnosis (10.9 months) and median survival from SGS
diagnosis (6.6 months). This question the existence of a direct
correlation between aggressive treatment and a highly hostile
clinical course of SGS patients. Furthermore, with the same
survival time from recurrence for PGS and SGS patients, one
could speculate if SGS patients represent PGS unrecognized at
initial diagnosis due to tumor sampling bias not accounting
for extent and heterogenous localization of the sarcomatous
presentation in GS.
This study constitutes one of the largest cohorts of GS
patients receiving standardized therapy making a regular
comparison of treatment outcomes betweenGS and conventional
GBM possible. Although our findings are encouraging, several
limitations should be considered, most notably the retrospective
study design and the limited statistical power given sample
size. The study is disposed to selection bias considering
only patients with high pretreatment functional status receive
standardized therapy according with the Stupp’s regimen. In
addition, as the selection for histopathological reevaluation
was based upon description of sarcomatous components in
the histopathological reports and several histopathological
reports contained compendious descriptions, some GS tumors
might have gone undiscovered. Regardless, our findings are
generally consistent with the existing literature on GS providing
an important contribution to the understanding of these
rare tumors.
CONCLUSION
In this study we found that GS present a similar prognosis
as conventional GBM with modern standardized trimodality
therapy, indicating that GS may be managed similarly to
conventional GBM. Only one PGS patient presented with distant
metastasis, suggesting that the incidence of metastases among GS
patients may be lower than previously reported. Temporal tumor
location and MGMT promoter methylation were significantly
associated with survival among PGS patients, supporting the
relevance of future studies of RT/TMZ therapy treatment in GS
patients to include evaluation of these characteristics.
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